Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Jul 23

PMID 21779318

Citations 15

Authors

Eric Murillo-Rodriguez

Marcela Palomero-Rivero

Diana Millan-Aldaco

Oscar Arias-Carrion

Rene Drucker-Colin

Affiliations

Soon will be listed here.

Abstract

Background: Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are amides of fatty acids and ethanolamine named N-acylethanolamines or acylethanolamides. The hydrolysis of OEA and PEA is catalyzed by the fatty acid amide hydrolase (FAAH). A number of FAAH inhibitors that increase the levels of OEA and PEA in the brain have been developed, including URB597. In the present report, we examined whether URB597, OEA or PEA injected into wake-related brain areas, such as lateral hypothalamus (LH) or dorsal raphe nuclei (DRN) would promote wakefulness (W) in rats.

Methodology And Principal Findings: Male Wistar rats (250-300 g) were implanted for sleep studies with electrodes to record the electroencephalogram and electromyogram as well as a cannulae aimed either into LH or into DRN. Sleep stages were scored to determine W, slow wave sleep (SWS) and rapid eye movement sleep (REMS). Power spectra bands underly neurophysiological mechanisms of the sleep-wake cycle and provide information about quality rather than quantity of sleep, thus fast Fourier transformation analysis was collected after the pharmacological trials for alpha (for W; α = 8-12 Hz), delta (for SWS; δ = 0.5-4.0 Hz) and theta (for REMS; θ = 6.0-12.0 Hz). Finally, microdialysis samples were collected from a cannula placed into the nucleus accumbens (AcbC) and the levels of dopamine (DA) were determined by HPLC means after the injection of URB597, OEA or PEA. We found that microinjection of compounds (10, 20, 30 µg/1 µL; each) into LH or DRN during the lights-on period increased W and decreased SWS as well as REMS and enhanced DA extracellular levels.

Conclusions: URB597, OEA or PEA promoted waking and enhanced DA if injected into LH or DRN. The wake-promoting effects of these compounds could be linked with the enhancement in levels of DA and indirectly mediated by anandamide.

Citing Articles

Coordinated Regulation of CB1 Cannabinoid Receptors and Anandamide Metabolism Stabilizes Network Activity during Homeostatic Downscaling.

Ye M, Monroe S, Gay S, Armstrong M, Youngstrom D, Urbina F eNeuro. 2022; 9(6).

PMID: 36316118 PMC: 9663203. DOI: 10.1523/ENEURO.0276-22.2022.

Palmitoylethanolamide: A Natural Compound for Health Management.

Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R Int J Mol Sci. 2021; 22(10).

PMID: 34069940 PMC: 8157570. DOI: 10.3390/ijms22105305.

Specific shifts in the endocannabinoid system in hibernating brown bears.

Boyer C, Cussonneau L, Brun C, Deval C, Pais de Barros J, Chanon S Front Zool. 2020; 17(1):35.

PMID: 33292302 PMC: 7681968. DOI: 10.1186/s12983-020-00380-y.

Cannabinoids, Endocannabinoids and Sleep.

Kesner A, Lovinger D Front Mol Neurosci. 2020; 13:125.

PMID: 32774241 PMC: 7388834. DOI: 10.3389/fnmol.2020.00125.

-Palmitoylethanolamine Maintains Local Lipid Homeostasis to Relieve Sleep Deprivation-Induced Dry Eye Syndrome.

Chen Q, Ji C, Zheng R, Yang L, Ren J, Li Y Front Pharmacol. 2020; 10:1622.

PMID: 32047441 PMC: 6997544. DOI: 10.3389/fphar.2019.01622.

References

Dzirasa K, Ribeiro S, Costa R, Santos L, Lin S, Grosmark A . Dopaminergic control of sleep-wake states. J Neurosci. 2006; 26(41):10577-89. PMC: 6674686. DOI: 10.1523/JNEUROSCI.1767-06.2006. View

Mor M, Rivara S, Lodola A, Plazzi P, Tarzia G, Duranti A . Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem. 2004; 47(21):4998-5008. DOI: 10.1021/jm031140x. View

Murillo-Rodriguez E, Cabeza R, Mendez-Diaz M, Navarro L, Prospero-Garcia O . Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport. 2001; 12(10):2131-6. DOI: 10.1097/00001756-200107200-00018. View

Schwartz G, Fu J, Astarita G, Li X, Gaetani S, Campolongo P . The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 2008; 8(4):281-288. PMC: 2572640. DOI: 10.1016/j.cmet.2008.08.005. View

Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J . An anorexic lipid mediator regulated by feeding. Nature. 2001; 414(6860):209-12. DOI: 10.1038/35102582. View

Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O . Anandamide modulates sleep and memory in rats. Brain Res. 1998; 812(1-2):270-4. DOI: 10.1016/s0006-8993(98)00969-x. View

Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S . Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem. 2003; 46(12):2352-60. DOI: 10.1021/jm021119g. View

Calignano A, La Rana G, Piomelli D . Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001; 419(2-3):191-8. DOI: 10.1016/s0014-2999(01)00988-8. View

Llinas R, Steriade M . Bursting of thalamic neurons and states of vigilance. J Neurophysiol. 2006; 95(6):3297-308. DOI: 10.1152/jn.00166.2006. View

10.

Ahn K, McKinney M, Cravatt B . Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 2008; 108(5):1687-707. PMC: 3150828. DOI: 10.1021/cr0782067. View

11.

Corsi-Cabrera M, Perez-Garci E, Del Rio-Portilla Y, Ugalde E, Guevara M . EEG bands during wakefulness, slow-wave, and paradoxical sleep as a result of principal component analysis in the rat. Sleep. 2001; 24(4):374-80. DOI: 10.1093/sleep/24.4.374. View

12.

Zahm D, Heimer L . Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J Comp Neurol. 1993; 327(2):220-32. DOI: 10.1002/cne.903270205. View

13.

Murillo-Rodriguez E, Arias-Carrion O, Sanguino-Rodriguez K, Gonzalez-Arias M, Haro R . Mechanisms of sleep-wake cycle modulation. CNS Neurol Disord Drug Targets. 2009; 8(4):245-53. DOI: 10.2174/187152709788921654. View

14.

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G . Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2004; 313(1):352-8. DOI: 10.1124/jpet.104.078980. View

15.

Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colin R . The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci. 2008; 122(6):1378-82. DOI: 10.1037/a0013278. View

16.

Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F . Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003; 425(6953):90-3. DOI: 10.1038/nature01921. View

17.

Steriade M . Grouping of brain rhythms in corticothalamic systems. Neuroscience. 2005; 137(4):1087-106. DOI: 10.1016/j.neuroscience.2005.10.029. View

18.

Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani P . Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep. 2004; 26(8):943-7. DOI: 10.1093/sleep/26.8.943. View

19.

Jones B . From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci. 2005; 26(11):578-86. DOI: 10.1016/j.tips.2005.09.009. View

20.

Santucci V, Storme J, Soubrie P, Le Fur G . Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 1996; 58(6):PL103-10. DOI: 10.1016/0024-3205(95)02319-4. View